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Tumor suppressor/transcription factor p53 is mutated in over 50% of all cancers.
Some mutant p53 proteins have not only lost tumor suppressor activities but they also gain oncogenic functions (GOF). One of the most frequently expressed GOF p53 mutants is Arg175His (p53 R175H showed that p53 R175H expression in plakoglobin null cells increased total and nuclear levels of b-catenin and its transcriptional activity. Coexpression of plakoglobin in these cells promoted b-catenin's proteasomal degradation, and decreased its nuclear levels and transactivation. Wnt/b-catenin targets, c-MYC and S100A4 were upregulated in p53 R175H cells and were downregulated when plakoglobin was coexpressed.
Plakoglobin-p53 R175H cells also showed significant reduction in their migration and invasion in vitro.
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| INTRODUCTION
p53 is a sequence-specific transcription factor with tumor and metastasis suppressor activities. 1, 2 It plays pivotal roles in the regulation of the cell cycle, DNA repair, senescence, apoptosis, and metabolism by responding to various cellular stress signals such as DNA damage, hypoxia, mitotic stress, oncogenic signaling etc. 3, 4 As a transcription factor, p53 downregulates the expression of genes involved in tumor development and cancer progression. [5] [6] [7] p53 is mutated or lost in over half of all cancers and in more than 80% of metastatic tumors. 3, 8 In addition to the loss/partial loss of tumor suppressor activities, some p53 mutants also gain oncogenic functions (GOF) that contribute to tumor cell growth, aggressiveness, metastasis and drug resistance. 9 p53 inactivation can result from
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
genetic alterations, decreased stability, defective post-translational modifications and interaction with intracellular partners. 10 There are over 30 000 somatic mutations in TP53, including missense, nonsense, deletions, frameshifts and temperature sensitive.
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Most of these changes occur within the DNA-binding domain with more than 75% single missense mutations, 40% of which are represented by 6 hot spot mutations (Arg175, Gly245, Arg248, Arg249, Arg273 and Arg282) that are highly frequent in tumors of different origins. 11 Hot spot mutations are further classified into 2 groups: contact mutations (Arg248, Arg273) inhibit direct interaction between p53 and DNA leading to a loss of sequence-specific transactivation, whereas structural mutations (Arg175, Gly245, Arg249, and Arg282)
alter local or global conformation of p53 causing indirect loss of DNA binding. 12 Among the hot spot structural mutations, Arg175His
(R175H), is the most frequent GOF p53 mutant 13, 14 that increases cancer cell proliferation, migration and invasion by deregulating different signaling pathways involved in tumorigenesis and metastasis.
p53 functions are regulated by post-translational modifications and protein-protein interactions. 15 We have identified plakoglobin (c-catenin) as an endogenous interacting partner of wild type as well as a number of most frequent mutant p53 (mp53) in various carcinoma cell lines of different origins and have shown that its interaction with mp53 restores mp53 tumor suppressor activities in vitro. [16] [17] [18] [19] Plakoglobin is an armadillo protein family member and is a paralog of b-catenin with similar dual cell-cell adhesion and signaling activities. 20, 21 However, unlike b-catenin that acts as an oncogene through its interaction with the transcription factors T-cell factor/ lymphoid enhancer-binding factor (TCF/LEF), and activation of Wnt signaling pathway, 22, 23 plakoglobin generally acts as a tumor/metastasis suppressor. 20, 21, [24] [25] [26] [27] We have shown that plakoglobin can act as a tumor/metastasis suppressor by at least 3 mechanisms: regulation of stability and subcellular localization of growth regulating molecules, 19, 25, 28 interaction with transcription factors involved in the regulation of cell growth and metastasis [16] [17] [18] [19] 25 and sequestration of b-catenin oncogenic activities; 29 see also. [30] [31] [32] [33] [34] p53 GOF mutations can induce aberrant accumulation and increased transcriptional activation of b-catenin in cancer cells. [35] [36] [37] In the absence of Wnt, excess cytoplasmic b-catenin is degraded by phosphorylation and proteasomal degradation. [38] [39] [40] Upon Wnt activation, b-catenin is stabilized and translocates into the nucleus where it binds to TCF/LEF and activates the expression of Wnt targets including cyclin D1, c-Myc, MMPs, S100A4, and survivin etc. [38] [39] [40] [41] [42] [43] This triggers an epithelial to mesenchymal phenotypic transition, cell proliferation, migration, invasion and metastasis. 41, 43 b-Catenin is also degraded through its ubiquitination by Siah-1, an E3 ubiquitin ligase that enhances b-catenin's proteasomal degradation independent of the canonical Wnt signaling pathway. 44, 45 In the present study, our goal was to assess the effects of GOF 
| Plasmid construction and transfection
Hemagglutinin (HA)-tagged p53 has been described previously. 18, 46 The pcDNA3.1/hygro-plakoglobin construct was generated using the previously described FLAG-tagged plakoglobin as a template. 29 The p53 R175H expression construct was a gift from Dr Giovanni Blandino.
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H1299 cells were cultured in 60-mm dishes and transfected at 60% confluency with 9 lg DNA using calcium phosphate. were centrifuged at 14 000 g for 2 minutes and supernatants were separated and processed for a second immunoprecipitation for 3 hours. Beads from the 2 immunoprecipitations were combined and washed 3 times with the lysis buffer. Immune complexes were solubilized in 60 lL SDS sample buffer, separated by SDS-PAGE and processed for western blot (WB) as described above.
| Immunofluorescence and confocal microscopy
Immunofluorescence and confocal microscopy were carried out as described in detail previously. 48 For real-time PCR, SYBR Green Master Mix (Thermo Fisher Scientific) and specific forward and reverse primers for MYC, S100A4
and ACTB (b-actin) ( Table 2) were used according to the manufacturer's instructions.
| Proteasome inhibition assay
Replicate 100 mm cultures remained untreated or were treated with 1 lmol/L proteasome inhibitor MG132 (Sigma Chemical Co., St
Louis, MO, USA) for 16 hours. Untreated and treated cells were then lysed and total cell lysates were used for western blot with b-catenin antibodies as described above. 
T A B L E 1 Antibodies and their respective dilutions in specific assays

| In vitro migration and invasion assays
Migration and invasion assays were carried out using Transwell inserts (BD Biosciences, Franklin Lakes, NJ, USA) as described in detail previously. 18 The migrated/invaded cells were counted in 5 random fields for each membrane using the NIH ImageJ Cell Counter program. Numbers for each cell line were averaged and normalized to those of the parental untransfected cells and histograms constructed. Histograms represent the average AE SD of 3-6 independent assays for each cell line.
| Statistical analysis
Values are presented as means AE SD. Statistical differences between groups were assessed by Student's t tests. P-value <.05 was considered significant.
3 | RESULTS
| Plakoglobin interacted with p53
R175H and decreased b-catenin protein levels
We first validated the expression of plakoglobin, p53 and p53
R175H
in single and double H1299 transfectants by processing total cell extracts from all transfectants for western blots with plakoglobin and p53 antibodies ( Figure 1A ).
Previously, we have shown that plakoglobin interacted with p53 and several mp53 proteins using different carcinoma cell lines. [16] [17] [18] [19] To verify plakoglobin interaction with p53 residues by GSK3b, which enables the protein to bind to E3 ubiquitin ligase TrCP1 (b-TrCP) and marks it for proteasomal degradation. 51, 52 The second degradation pathway is mediated by Siah1 and is independent of GSK3b. Siah1 is a target of p53 and E2F1 and is minimally expressed in H1299 cells, 53, 54 suggesting that decreased b-catenin levels in plakoglobin-expressing H1299 cells is likely as a result of the increased proteasomal degradation by GSK3b. To address this possibility, we used MG132, which inhibits 20S proteasome activity and degradation of ubiquitinated proteins. Blots were also probed with b-actin antibodies to confirm equal protein loadings. E, Blots in (C) were quantitated and histograms were generated that represent the average AE SD of 4 separate experiments. All values were normalized to the untransfected and untreated cells. *P < .05; **P < .001. UT, untransfected; b-cat, b-catenin
( Figure 4B ). In contrast, relative to parental H1299 cells, H1299-p53 R175H transfectants showed over 60% higher luciferase activity ( Figure 4B ), which was significantly reduced when plakoglobin was coexpressed in these cells ( Figure 4B , H1299-PG-p53 R175H ).
Based on these observations, we reasoned that decreased bcatenin/TCF transactivation should result in decreased expression of their target genes. Specifically, we focused on c-MYC and S100A4, 2 b-catenin/TCF target genes that are known to participate in tumorigenesis and metastasis. [41] [42] [43] [57] [58] [59] RT-qPCR experiments showed that the levels of c-MYC and S100A4 mRNA were significantly increased in H1299-p53 R175H transfectants compared to H1299 cells (Figure 4C) . Coexpression of plakoglobin in these cells (H1299-PGp53 R175H ) led to over 3-and 5-fold decrease in c-MYC and S100A4 mRNA levels, respectively ( Figure 4C ). Together, the results of the experiments in Figure 4 suggested that plakoglobin expression in As shown in Figure 5A , p53 and plakoglobin expression decreased migration by 45% and 34% relative to H1299 cells, respectively, whereas coexpression of both proteins reduced migration by 73% (Figure 5A , migration; H1299-p53, H1299-PG and H1299-PG-p53; also see 18 ). In contrast, expression of p53 R175H increased the migration of H1299 cells by~20% ( Figure 5A , migration, H1299-p53 R175H ), which was reduced by >40% when plakoglobin was coexpressed ( Figure 5A , H1299-PG-p53 R175H ).
Similarly, the invasiveness of H1299-p53 and H1299-PG cells was decreased by 60% and 33%, respectively, whereas the invasive- gene. 70, 71 In the present study, we used invasive and metastatic H1299 cells with the activated Wnt/b-catenin pathway. 72 This cell line is plakoglobin deficient and p53 null and has been extensively used to assess the function of p53 and p53 mutants. We showed that the expression of p53 R175H increased b-catenin levels, its interaction with TCF and activation of c-MYC and S100A4, 2 known b-catenin/ TCF target genes. [41] [42] [43] [57] [58] [59] Increased b-catenin levels and activation were concurrent with increased migration and invasion of p53 R175H -expressing cells. We further showed that the oncogenic effects of [38] [39] [40] [41] [42] [43] [44] [45] In the absence of Wnt signal, Axin/APC/ GSK3b/CKI forms the destruction complex that recruits and phosphorylates excessive cytoplasmic b-catenin, which is subsequently ubiquitinated and degraded by the proteasome pathway. [38] [39] [40] In the presence of Wnt, the destruction complex is inactivated and the sta- antibodies. Equal loadings were confirmed by processing total cell extracts from all cell lines for immunoblotting using b-actin antibodies. B, Untransfected H1299 cells and H1299 transfectants were cotransfected with pTOPFLASH b-catenin/TCF reporter construct and p-RL-TK Renilla reporter plasmid and luciferase activities were measured 48 h post-transfection. Levels of luciferase activities from pTOPFLASH were normalized to those of Renilla plasmid. Four independent experiments were carried out and the results were normalized to H1299 parental cells. SW620 cells were included as a positive control. UT, untransfected. *P < .05, **P < .001. C, Total cellular RNA was extracted from untransfected H1299 cells and H1299 transfectants, reverse transcribed and processed for real-time PCR for C-MYC (top) and S100A4 (bottom) using specific primers (Table 2) . Expression levels were first normalized to the amount of ACTB in the same cell line and then to H1299 untransfected cells. Histograms were constructed based on the average AE SD. UT, untransfected. *P < .05, **P < .001 S37, S45, T41) required for its degradation also activate b-catenin in the absence of the Wnt signal. 73, 74 In agreement with previous reports, we showed that wild-type p53 expression in H1299 cells reduced the total and nuclear b-catenin levels and its transcriptional activity. There are several mechanisms by which p53 reduces b-catenin protein levels and activation.
p53 interacts with and activates GSK3b and/or accelerates the movement of the scaffolding protein, Axin, into the destruction complex, both of which lead to increased phosphorylation of b-catenin and its subsequent degradation. 75, 76 p53 also inhibits the activity of CK2, which phosphorylates and protects b-catenin from proteasomal degradation. 77 Furthermore, p53 can inhibit the Wnt pathway by inducing the expression of the Wnt antagonizer, Dickkopf-1, the E3 ubiquitin ligase Siah1 that mediates the degradation of b-catenin independent of the GSK3b and miR-34 tumor suppressor, which inhibits the expression of several components of the Wnt pathway. 44, 45, [78] [79] [80] In contrast, GOF mutant p53 have been shown to inhibit b-catenin degradation and promote its oncogenic activities and suppress miR-34 expression. [35] [36] [37] 44, 45, 79, 81 Here, we showed that p53 R175H expression significantly reduced b-catenin degradation through the proteasome pathway. p53
-expressing cells had increased total and nuclear b-catenin and b-catenin/TCF reporter activity and showed upregulation of the Wnt target genes. [41] [42] [43] [57] [58] [59] Previously, we have shown that plakoglobin interacted with both wild type and a number of mutant p53 proteins and this interaction was direct (data not shown) and mediated by the DNA-binding domain of p53 and the C-terminal transactivation domain of plakoglobin. [16] [17] [18] [19] We showed that plakoglobin and p53 associated with promoters of a number of p53 target genes including tumor suppressors SFN (14-3-3d) and NME1 and the oncogenic genome organizer SATB1. [16] [17] [18] [19] Furthermore, plakoglobin expression in plakoglobin-deficient and mp53-expressing cells reduced growth, migration and invasion of these cells in vitro. 16, 17, 19 Plakoglobin has also been shown to regulate the expression of HAI-1 and to reduce migration in a p53-dependent way in NSCLC cells. 27 Coimmunoprecipitation experiments indicated that plakoglobin interacted with p53.
Furthermore, expression of plakoglobin in p53 R175H cells promoted b-catenin's proteasomal degradation and significantly reduced its total and nuclear levels, as had been reported previously. 82 Plakoglobin expression also reduced b-catenin/TCF-4 interaction, and the F I G U R E 5 A, Plakoglobin (PG) reduced in vitro migration and invasion of p53R175H-expressing H1299 cells. H1299 and H1299 transfectants were processed for 24-h Transwell migration and invasion assays as described in Materials and Methods. Number of migrated/ invaded cells in 5 random fields were counted using ImageJ cell counter program. Four separate experiments were carried out for each cell line and the histograms represent the average AE SD of the number of the migrated/invaded cells for each cell line. All values were normalized to H1299 untransfected cells. UT, untransfected. *P < .05, **P < .001. B, Hypothetical model for restoration of tumor-suppressor activity of mutant p53 by plakoglobin. p53 enhances b-catenin's proteasomal degradation by increasing the assembly of the destruction complex and/or inducing the expression of Siah-1, whereas mp53 inhibit b-catenin degradation (see text for details). This would lead to increased stability and translocation of b-catenin to the nucleus and transactivation of target genes in mp53-expressing cells. Based on the current study and our previous findings, plakoglobin may counteract the oncogenic function of mutant p53 by increasing b-catenin's proteasomal degradation and by restoring tumor-suppressor activities of mutant p53 through enabling their interaction with promoters of wild-type p53 target genes 16, 17 or modifying mutant p53 target gene expression. 16 TCF, T-cell factor expression of c-MYC and S100A4. These observations are also supported by our previous microarray studies, which identified p44 and p56 of the 26S proteasome and S100A4 as transcripts that were upregulated and downregulated, respectively, in plakoglobin- 
